Abstract
The cells of the human body have a receptor that is sensitive to extracellular calcium [calcium-sensing receptor (CaSR)] and whose tissue expression is decreased in patients with chronic kidney disease. The CaSR plays a key role both in the regulation of PTH secretion by parathyroid cells, as well as in calcium tubular reabsorption by renal tubular cells. Recent biochemical and cellular studies found that this receptor has peculiar functional characteristics. Furthermore, pharmacological research has brought to the marker agonists for CaSR (calcimimetics) that today are used for treating secondary hyperparathyroidism and may have an effect on cardiovascular and bone diseases in patients with chronic kidney disease. With regard to the latter, the EVOLVE and ADVANCE trials were dedicated to understanding the role of cinacalcet, a calcimimetic drug, in the prevention of vascular calcification and cardiovascular events in patients with chronic kidney disease. Research in this field has thus opened promising p...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
